Cartilage damage in the knee aﬀects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiﬀness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaﬀold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaﬀold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
INTRODUCING PROVASCTEC : A CELL THERAPY FOR PATIENTS WITH CRITICAL LIMB ISCHEMIA
PRESS RELEASE March 20, 2023 ProVascTec, an NLC venture, will help patients with critical limb ischemia by triggering cell induced new vascular tissue growth. …
INTRODUCING HEAT2MOVE: A NON-MEDICAL AND NON-INVASIVE PAIN RELIEVING TECHNOLOGY
PRESS RELEASE March 6, 2023 HEAT2MOVE, an NLC venture, sets out to provide a home care chronic pain relief option that is based on…
INTRODUCING ANSANA: A NEW STERILIZATION TECHNOLOGY FOR THE HEALTHCARE & PHARMACEUTICAL INDUSTRY.
PRESS RELEASE February 28, 2023 Ansana, an NLC venture, is on a mission to develop and launch a cutting-edge system for observing and confirming…